Cargando…

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study

BACKGROUND AND AIMS: Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV‐infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2/3, nonrandomized, open‐label study evaluating the pharmacokinetics, efficacy, and safety of a pediatric f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonas, Maureen M., Rhee, Susan, Kelly, Deirdre A., Del Valle‐Segarra, Antonio, Feiterna‐Sperling, Cornelia, Gilmour, Susan, Gonzalez‐Peralta, Regino P., Hierro, Loreto, Leung, Daniel H., Ling, Simon C., Lobzin, Yuri, Lobritto, Steven, Mizuochi, Tatsuki, Narkewicz, Michael R., Sabharwal, Vishakha, Wen, Jessica, Kei Lon, Hoi, Marcinak, John, Topp, Andrew, Tripathi, Rakesh, Sokal, Etienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548879/ https://www.ncbi.nlm.nih.gov/pubmed/33811356 http://dx.doi.org/10.1002/hep.31841

Ejemplares similares

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study
por: Jonas, Maureen M., et al.
Publicado: (2019)

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
por: Brown, Robert S., et al.
Publicado: (2022)

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
por: Feld, Jordan J., et al.
Publicado: (2022)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021)

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
por: Forns, Xavier, et al.
Publicado: (2021)

Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021)

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial
por: Madsen, Lone W., et al.
Publicado: (2022)

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
por: Arora, Rishi, et al.
Publicado: (2023)

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
por: Yap, Desmond Y. H., et al.
Publicado: (2020)

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
por: Back, David, et al.
Publicado: (2019)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
por: Zamor, Philippe J., et al.
Publicado: (2021)

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
por: Yamana, Yoichiro, et al.
Publicado: (2021)

Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C
por: Fansiwala, Kush, et al.
Publicado: (2021)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
por: Toyoda, Hidenori, et al.
Publicado: (2017)

1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks
por: Sarrazin, Christoph, et al.
Publicado: (2018)

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
por: Foster, Graham R., et al.
Publicado: (2019)

Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis
por: Xu, Hong-Qin, et al.
Publicado: (2020)

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
por: Flamm, Steven, et al.
Publicado: (2018)

A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis
por: Yoon, Jae Hyun, et al.
Publicado: (2019)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir
por: Totsuka, Mai, et al.
Publicado: (2021)

Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine
por: Kosloski, Matthew P., et al.
Publicado: (2023)

The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort
por: Yaras, Serkan, et al.
Publicado: (2023)

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
por: Martinello, Marianne, et al.
Publicado: (2023)

Hepatitis C virus treatment with glecaprevir and pibrentasvir in patients co-prescribed carbamazepine: Three case reports
por: Braude, Michael, et al.
Publicado: (2023)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
por: Gane, Edward, et al.
Publicado: (2019)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Efficacy and safety of glecaprevir and pibrentasvir combination therapy in old-aged patients with chronic hepatitis C virus infection
por: Watanabe, Shunji, et al.
Publicado: (2020)

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
por: Flamm, Steven L., et al.
Publicado: (2020)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older
por: Komaki, Yuri, et al.
Publicado: (2022)

Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
por: Park, Young Joo, et al.
Publicado: (2021)

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
por: Aghemo, Alessio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p44csialoghtg0rm48hsml2hhh